Does Estrogen Increase Breast Cancer Risk?
There is no single yes-or-no answer for every type of hormone therapy.
The best-known randomized evidence comes from the Women’s Health Initiative (WHI). Its long-term results showed two different patterns:
- Estrogen alone: Among women who had undergone hysterectomy, conjugated equine estrogen was associated with lower breast cancer incidence and breast cancer mortality compared with placebo.
- Estrogen plus progestin: Among women with a uterus, conjugated equine estrogen plus medroxyprogesterone acetate was associated with higher breast cancer incidence (Chlebowski et al., 2020).
That does not mean estrogen always protects against breast cancer or that every combined hormone treatment carries the same risk. Breast cancer risk can vary with the hormone regimen, duration of treatment, age, medical history, and other individual risk factors (The North American Menopause Society [NAMS], 2022).
What Did the Women’s Health Initiative Find?
The WHI included two separate randomized hormone therapy trials.
One trial enrolled 16,608 postmenopausal women with a uterus. Participants received either conjugated equine estrogen plus medroxyprogesterone acetate or placebo.
The combination trial was stopped early in 2002 after approximately five years because the overall balance of benefits and risks was considered unfavorable.
Long-term follow-up later showed breast cancer incidence of approximately:
- 0.45% per year with estrogen plus progestin vs. 0.36% with placebo.
This represented a 28% relative increase in breast cancer incidence (Chlebowski et al., 2020).
A separate WHI trial studied 10,739 women who had undergone hysterectomy. They received conjugated equine estrogen alone or placebo.
During long-term follow-up, breast cancer incidence was approximately:
- 0.30% per year with estrogen alone vs. 0.37% with placebo.
Estrogen alone was also associated with lower breast cancer mortality in this group (Chlebowski et al., 2020).
These findings are important, but they apply specifically to the formulations and populations studied in the WHI. They should not be interpreted to mean that all forms of estrogen or hormone therapy produce identical results.
Why Do Other Studies Give Different Answers?
This is where discussions about HRT and breast cancer can become confusing.
A large 2019 analysis of observational studies found an increased breast cancer risk with most types of systemic menopausal hormone therapy. The increase was greater with estrogen-progestogen therapy than with estrogen alone and generally became larger with longer use (Collaborative Group on Hormonal Factors in Breast Cancer, 2019).
That appears different from the estrogen-only WHI result, but the studies were designed differently.
The WHI was a randomized clinical trial involving specific medications and defined patient groups. Observational studies examine women using a wider range of hormone formulations, treatment durations, and prescribing patterns in routine life (Chlebowski et al., 2020; Collaborative Group on Hormonal Factors in Breast Cancer, 2019).
For that reason, one study should not be used to make a blanket statement such as “estrogen causes breast cancer” or “estrogen prevents breast cancer.”
The more accurate conclusion is that breast cancer risk differs according to the type of hormone therapy and the individual using it.
Does the Type of Hormone Therapy Matter?
Yes.
Women who still have a uterus generally need a progestogen alongside systemic estrogen to protect the uterine lining from endometrial hyperplasia and cancer. Women who have had a hysterectomy may be able to use estrogen without a progestogen (NAMS, 2022).
Modern menopausal hormone therapy also includes options that were not directly tested in the original WHI trials, including transdermal estradiol and micronized progesterone.
Research continues to examine whether different formulations and routes have different long-term breast cancer risk profiles. Current evidence does not justify assuming that every modern HRT regimen has exactly the same risks as the medication combinations used in the WHI (NAMS, 2022).
What About the FDA’s HRT Warning?
Hormone therapy labeling has also changed.
In November 2025, the FDA began requesting changes to the boxed warnings on menopausal hormone therapy products. In February 2026, the FDA approved updated labeling for an initial group of products that removed boxed-warning statements concerning breast cancer, cardiovascular disease, and probable dementia (U.S. Food and Drug Administration [FDA], 2026).
This does not mean HRT has no risks.
Breast cancer and cardiovascular risk information remains relevant when deciding whether systemic hormone therapy is appropriate. The labeling changes are intended to provide a more individualized interpretation of the evidence rather than applying the original WHI warnings broadly to every menopausal hormone therapy product (FDA, 2026).
Who Should Be More Cautious About HRT?
Hormone therapy decisions should consider more than breast cancer risk alone.
Your clinician should review factors such as:
- Personal history of breast or endometrial cancer
- Whether you still have a uterus
- Family history of breast cancer
- Previous blood clots, stroke, or cardiovascular disease
- Age and time since menopause
- Current breast cancer screening
- Type, dose, route, and expected duration of hormone therapy
Systemic hormone therapy is generally not recommended for women with a history of breast cancer unless it is being considered in an exceptional situation with appropriate specialist involvement (NAMS, 2022).
For otherwise healthy women with bothersome menopausal symptoms, major menopause guidelines emphasize individualized decision-making rather than treating HRT as universally safe or universally dangerous (NAMS, 2022).
So, Does HRT Cause Breast Cancer?
The most accurate answer is:
Some hormone therapy regimens are associated with increased breast cancer risk, while the risk appears different with estrogen-only therapy. There is not enough evidence to make the blanket claim that all estrogen therapy either causes or prevents breast cancer.
In the WHI randomized trials, estrogen plus medroxyprogesterone acetate increased breast cancer incidence, while conjugated equine estrogen alone in women with prior hysterectomy was associated with lower incidence (Chlebowski et al., 2020).
Other research has found increased risk with longer use of menopausal hormone therapy, particularly combined estrogen-progestogen therapy (Collaborative Group on Hormonal Factors in Breast Cancer, 2019).
That is why the decision should be based on your symptoms, medical history, breast cancer risk, uterus status, treatment goals, and the specific therapy being considered (NAMS, 2022).
Making an HRT Decision at Androgenix
If hot flashes, night sweats, sleep disruption, or other menopause symptoms are affecting your quality of life, fear from a headline published more than 20 years ago should not be the only factor determining your decision.
At Androgenix in North Palm Beach, we review your symptoms, medical and family history, current screening, individual risk factors, and treatment goals before discussing whether hormone therapy may be appropriate.
The goal is not to tell every woman that HRT is right for her. It is to help you understand the potential benefits and risks clearly enough to make an informed decision.
Have questions about HRT and your individual breast cancer risk? Schedule a consultation with Androgenix in North Palm Beach to discuss your options.
Frequently Asked Questions About Estrogen and Breast Cancer
Does estrogen cause breast cancer?
There is no simple yes-or-no answer. In the WHI randomized trial, women with a prior hysterectomy who took estrogen alone had fewer breast cancer diagnoses than those who took placebo (Chlebowski et al., 2020). However, observational studies have found increased risk with some forms and durations of estrogen therapy (Collaborative Group on Hormonal Factors in Breast Cancer, 2019). Risk depends on the type of therapy, duration of use, and individual health history.
Does HRT increase breast cancer risk?
Some types can. In the WHI, estrogen combined with medroxyprogesterone acetate was associated with higher breast cancer incidence, while estrogen alone was associated with lower incidence among women who had undergone hysterectomy (Chlebowski et al., 2020). This is why HRT decisions should consider the specific treatment being used rather than treating all hormone therapy as having the same risk.
Did the FDA remove the boxed warning on HRT?
The FDA began updating HRT labeling in November 2025, requesting removal of boxed-warning language about breast cancer, cardiovascular disease, and probable dementia. Updated labeling has since been approved for several menopausal hormone therapy products. The boxed warning for endometrial cancer remains on systemic estrogen-only products for women with a uterus (FDA, 2026).
These changes do not mean HRT is risk-free. Breast cancer and cardiovascular risks may still be included elsewhere in product labeling and should be discussed with healthcare professionals
Medical Disclaimer
This article is for educational purposes only and does not replace individualized medical advice, diagnosis, or treatment. Hormone therapy has benefits and risks that vary from person to person. Discuss your medical history and treatment options with a qualified healthcare professional.
